Clinical profiles and their interaction of concurrent metabolic associated steatotic liver disease and hepatitis B virus infection

doi:10.4254/wjh.v16.i12.1429

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (972)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

HTML

468

Figures (1-3)

Tables (1-5)

Sum=632

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

140

Sum=235

Publishing Process of This Article

Item

Count

Browse

Download

Sum=67

Dec 27, 2024 (publication date) through Jan 10, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Dec 27, 2024; 16(12): 1429-1440
Published online Dec 27, 2024. doi: 10.4254/wjh.v16.i12.1429

Full Size Figure Download Figure

Figure 3 Patients with positive hepatitis B surface antigen were distributed to two groups based on the status of metabolic dysfunction-associated steatotic liver disease. anti-HBc: Hepatitis B core antibodies; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; MASLD: Metabolic dysfunction-associated steatotic liver disease.

Citation: Wang SW, Chang YW, Wang C, Cheng YM, Hsieh TH, Wang CC, Kao JH. Clinical profiles and their interaction of concurrent metabolic associated steatotic liver disease and hepatitis B virus infection. World J Hepatol 2024; 16(12): 1429-1440
URL: https://www.wjgnet.com/1948-5182/full/v16/i12/1429.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i12.1429